Registration |Grand Ballroom Registration Desk

Networking Reception and Table-Top Exhibits |Renaissance Ballroom

Registration |Grand Ballroom Registration Desk

Networking Breakfast and Table-Top Exhibits |Renaissance Ballroom

Opening Remarks |Grand Ballroom

 

Perry L. Fri, Executive Vice President, Industry Relations, Membership & Education and COO, HDA Research Foundation, Healthcare Distribution Alliance

FDA Overview and Update |Grand Ballroom

FDA has issued a record number of guidances in draft or final form, as well as held a number of public meetings over the last year on DSCSA implementation. This session will provide an opportunity to hear directly from the Agency on upcoming DSCSA milestones, as well as their expectations for the pharmaceutical supply chain.

Ilisa B.G. Bernstein, JD, PharmD, SVP, Pharmacy Practice and Government Affairs, American Pharmacists Association

Networking Break and Table-Top Exhibits |Renaissance Ballroom

Sponsored by  

Verification Router Service (VRS) Update |Grand Ballroom

Since 2016, HDA has convened industry and solution providers to develop the technical specifications necessary to build a Verification Router Service (VRS) network to comply with the 2019 saleable returns requirement.  In this interactive session, VRS testing participants will discuss what the network is, share what they have learned through the process to date and planned testing activities, what to consider as companies set up their system to connect to the VRS network, how and when to connect, and critical success factors. Attendees will have the opportunity to share their experiences and provide feedback through facilitated discussions and polling.

	David Colombo, Director, Life Sciences Advisory Services, KPMG, LLP
	Michael Rowe,
	Matt Sample, V.P., Manufacturer Operations, AmerisourceBergen Corporation
	Allison Sheldon, Senior Manager, Pfizer Digital Serialization, Pfizer Inc.

Networking Luncheon and Table-Top Exhibits |Renaissance Ballroom

Panel Discussion: HDA Perspective on FDA Guidance |Grand Ballroom

FDA has had an active year, releasing a variety of guidance documents and holding three public meetings on DSCSA implementation. Panelists will review the key highlights from these activities and share their perspective on implications for compliance.

	Anita T. Ducca, Senior Vice President, Regulatory Affairs, Healthcare Distribution Alliance
	Tish E. Pahl, Principal, Olsson Frank Weeda Terman Matz PC
	Brian P. Waldman, Esq. MBA, Partner, Arent Fox LLP

A Vision for 2023 |Grand Ballroom

As the supply chain reaches the halfway point between the DSCSA’s enactment and its endpoint, more attention is being paid to its ultimate goals. At the 2017–2018 FDA public meetings, stakeholders caught a glimpse of what the Agency, and other industry stakeholders, are anticipating for 2023. Panelists will provide perspectives from each sector of the supply chain on how they plan to meet the 2023 requirements.

	Perry L. Fri, Executive Vice President, Industry Relations, Membership & Education and COO, HDA Research Foundation, Healthcare Distribution Alliance
	Andrew Meyer, Director of Supply Chain , LSPediA
	Scott A. Mooney, Vice President, Distribution Operations, McKesson Corporation